Follistatin-344

WHAT IT IS

Follistatin is a protein the human body naturally produces. FS344 is one of its naturally occurring splice variants, chosen in research because it binds myostatin with less off-target binding than some other follistatin forms.

In muscular dystrophy research, follistatin has mostly been studied by delivering its gene into muscle tissue using an adeno-associated virus vector, rather than by injecting a synthesized protein or peptide directly, though synthesized versions are also sold to researchers.

It is not an approved medicine. Human research has so far been confined to small, early-phase gene-therapy trials in rare muscle diseases. FDA status: Follistatin-344 is not FDA-approved as a treatment for any condition.

WHAT RESEARCHERS ARE STUDYING IT FOR

Published and registered research on follistatin-344 has focused on:

• Becker muscular dystrophy, a milder dystrophin-deficiency condition than Duchenne
• Sporadic inclusion body myositis, an inflammatory muscle-wasting condition
• Duchenne muscular dystrophy, in a related but separate gene-therapy trial
• Muscle fiber size, strength and walking distance as gene-therapy outcome measures

PROPOSED BIOLOGICAL MECHANISMS

Follistatin binds myostatin and activin, preventing them from signaling through the ActRIIB receptor that normally restrains muscle fiber growth, similarly in concept to receptor-trap approaches like ACE-031 but acting further upstream by binding the ligand directly.

In the Becker muscular dystrophy gene-therapy trial, researchers delivered the FS344 gene directly into thigh muscle using an AAV1 viral vector so that muscle cells themselves would produce the protein locally.

Muscle biopsies in that trial reportedly showed reduced fibrosis, more normal fiber size distribution and muscle fiber hypertrophy, particularly at the higher dose studied.

AREAS OF RESEARCH INTEREST

• Whether local, muscle-targeted gene delivery can produce meaningful functional benefit in dystrophin-deficient disease
• Long-term safety of AAV-delivered follistatin gene therapy, since the studied approach is not reversible in the way an injected protein or peptide would be
• Whether findings from small rare-disease trials generalize to broader muscle-wasting or age-related muscle loss research
• How a synthesized follistatin-344 peptide or protein product would compare to the gene-therapy approach actually studied in humans

WHAT THE EVIDENCE CURRENTLY SUGGESTS

The only meaningful human evidence comes from a small, six-patient Phase I/IIa Becker muscular dystrophy and inclusion body myositis gene-therapy trial. It reported improved walking distance on the 6-minute walk test in most but not all treated patients and no serious adverse events, alongside favorable biopsy findings.

A related, similarly small trial explored the same gene-therapy approach in Duchenne muscular dystrophy.

These are early-phase, small-sample studies without a placebo-controlled comparison group of the same scale as larger drug trials, so the findings are encouraging but preliminary rather than established treatment evidence. There is no human evidence at all evaluating an injected, synthesized follistatin-344 peptide product of the kind sold to consumers, which is a materially different intervention from the gene-therapy approach that was actually tested.